$MAZE

Coloma Jason V sold $725K of MAZE (indirect holdings)

Coloma Jason V (Chief Executive Officer) sold 27,858 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.04 ($26.00–$26.05, $0.73M total) across 3 trades over 2026-06-22 to 2026-06-23 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Coloma Jason V
Published Jun 24, 2026, 8:14 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 24, 2026, 8:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MAZE
Neutral
medium confidence
Mentioned
$MAZE
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MAZENeutralLow
01

Why it matters

The key new information is the disclosed sale size, timing, and that it was executed under a pre-arranged 10b5-1 plan; this typically has limited fundamental impact but can influence short-term sentiment.

02

Market read

Traders may briefly reassess positioning around MAZE due to insider selling, but the 10b5-1 structure reduces the likelihood of a strong negative signal.

03

What to watch

Indirect holdings and the post-transaction share count (319,079) may matter for interpreting whether the sale meaningfully changes economic exposure, but the article provides no additional context on total compensation or prior sale cadence.

Relevance 4/10Novelty 5/10Timing: Filed 2026-06-24 after-hours; reflects sales executed 2026-06-22 to 2026-06-23.

Background

The article is an SEC Form 4 insider transaction disclosure for Maze Therapeutics, Inc., identifying the CEO and the nature of the sale.

Company-level read

Ticker impact

$MAZENeutralMedium confidence
Context

SEC Form 4 shows CEO Coloma Jason V sold $725.5K of MAZE via an open-market sale under a 10b5-1 plan (27,858 shares).

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived unless accompanied by other company-specific catalysts.

Evidence & confidence

The disclosure is a Form 4 insider sale by the CEO, but it is explicitly pre-arranged under a Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal; this is company-specific insider transaction data with no stated sector-wide regulatory/clinical catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may be mechanically scheduled and not a bearish read-through; traders may ignore it unless there’s a pattern of unusually large discretionary selling.

Key entities

  • Maze Therapeutics, Inc.

    Subject of the Form 4 insider transaction; CEO sold shares totaling ~$725.5K at ~$26.04.

  • Coloma Jason V

    CEO and director; sold 27,858 shares across three trades (2026-06-22 to 2026-06-23) under a 10b5-1 plan.

Related articles